|
1
|
GPF003C-202: Lignosus Rhinocerus TM02® as a complementary therapy for uncontrolled asthma: A prospective, open-label, single-arm, phase II study; Principal Investigator: Poh ME.
|
|
2
|
TM02-PACOVIR: A randomised, double-blind, placebo-controlled trial investigating the use of TM02 as adjunctive treatment in post-acute COVID-19 patients with respiratory conditions; Principal Investigator: Wong CK.
|
|
3
|
EXACOS-MY: Exacerbations and Their Outcomes Among COPD Patients In Malaysia (EXACOS-MY): Understanding The Burden Of Severe Exacerbations Of COPD And The Association Between Frequency Of Severe Exacerbations And Clinical Outcomes In Malaysia; Principal Investigator: Wong CK.
|
|
4
|
MERIT: A Retrospective, Observational, Multicenter Study Evaluating Asthma Control in patients on Fluticasone propionate/Salmeterol PRD (Proactive Regular Dosing) with a history of uncontrolled asthma; Principal Investigator: Wong CK.
|
|
5
|
The Diagnostic Utility and Validity of Pleural Fluid Adenosine Deaminase Levels in the Diagnostic of Tuberculosis Pleural Effusion; Principal Investigator: Vijayan Munusamy.
|
|
1
|
OSTARA: A Phase II, Open-label, Single-arm, Multi-centre Study to Evaluate the Safety and Efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (OSTARA); Principal Investigator: Pang YK.
|
|
2
|
SB27-3004: A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in Subjects with Metastatic Non-squamous Non-small Cell Lung Cancer; Principal Investigator: Pang YK.
|
|
3
|
TroFuse-009 (MK2870-009): A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors; Principal Investigator: Pang YK.
|
|
4
|
TARGET: An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in participants with epidermal growth factor receptor mutation-positive Stage II-IIIB non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy; Principal Investigator: Pang YK.
|
|
5
|
CODEBREAK202: A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C; Principal Investigator: Pang YK.
|
|
6
|
ELEVA: TEA Randomized Double-blind, Four-arm Active and Placebo-controlled Dose-finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF); Principal Investigator: Pang YK.
|
| 7 |
MK7684A-003: Vibostolimab (MK-7684) With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer; Principal Investigator: Pang YK.
|
| 8 |
LASER301: A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib versus Gefitinib as the First-line Treatment in Patients with Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer; Principal Investigator: Pang YK.
|
| 9 |
ASPEN: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis; Principal Investigator: Pang YK.
|
| 10 |
Dizal DZ2019E0001: A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR (Exon20ins) or HER2 mutation; Principal Investigator: Pang YK
|
| 11 |
CADENCE-PRO-MAS-002: Biomarker discovery to differentiate between high-risk and lung cancer patients and as an adjunct test to imaging diagnosis to improve patient follow-up. Principal Investigator: Poh ME.
|
| 12 |
CAMEB2: Discovering airway resistotypes and clinical outcomes in bronchiectasis in a cohort of Asian and matched European bronchiectasis patients. Principal Investigator: Poh ME.
|
| 13 |
COPD ASIA: Define clinical, microbiological and inflammatory phenotype of Asian COPD patients: a multicenter, cross sectional and observational study. Principal Investigator: Poh ME.
|
| 14 |
AMASSMENT: Algorithm modelled & applied in Sabah for Smear Negative Pulmonary Tuberculosis, NIHR Global Health Research Unit On Respiratory Health (RESPIRE-2); Principal Investigator: Wong CK.
|
| 15 |
TILIA: A Phase Iii, Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Tozorakimab (Medi3506) In Patients Hospitalised For Viral Lung Infection Requiring Supplemental Oxygen; Principal Investigator: Wong CK.
|
| 16 |
AENS406: An observational study of afatinib 30 mg daily in patients with advanced non-small cell lung cancer (NSCLC) harbouring common EGFR mutations treated with afatinib; Principal Investigator: Wong CK.
|
| 17 |
LITHOS: A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma; Principal Investigator: Wong CK.
|
| 18 |
AJAX: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA; Principal Investigator: Wong CK.
|
| 19 |
MIRANDA: A Phase III, Multicentre, Randomised, Double-blind, Chronic dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations; Principal Investigator: Wong CK.
|
| 20 |
MARIPOSA-2: A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure; Principal Investigator: Tan JL.
|
| 21 |
PALOMA-3: A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous on Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy; Principal Investigator: Tan JL.
|
| 22 |
PALOMA-2: A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer; Principal Investigator: Tan JL.
|
| 23 |
POLYDAMAS: A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer; Principal Investigator: Tan JL.
|
| 24 |
COCOON: A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib; Principal Investigator: Tan JL.
|
| 25 |
V940-002: A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer; Principal Investigator: Tan JL.
|
| 26 |
SOHO-002: A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations; Principal Investigator: Tan JL.
|
| 27 |
CT-P51 3.1: A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination with Platinum-Pemetrexed Chemotherapy in Patients with Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer; Principal Investigator: Tan JL.
|
| 28 |
ARTEMIDE-Lung02: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1; Principal Investigator: Tan JL.
|
| 29 |
TRIDENT-3: A Randomized, Open-label, Multicenter,Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC); Principal Investigator: Tan JL.
|
Last Update: 14/11/2024